Holen Sie sich die Stockscreener-App
5.97
2.77%
-0.17
Handel nachbörslich:
5.96
-0.010
-0.17%
Schlusskurs vom Vortag:
$6.14
Offen:
$6.08
24-Stunden-Volumen:
1.08M
Relative Volume:
0.71
Marktkapitalisierung:
$248.17M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-3.1587
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
-2.29%
1M Leistung:
-29.68%
6M Leistung:
+359.23%
1J Leistung:
+198.50%
1-Tages-Spanne:
$5.92
$6.37
1-Wochen-Bereich:
$5.81
$6.6499
52-Wochen-Spanne:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.97 | 388.29M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Immuneering Corporation stock outlook for YEARMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com
How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Action & Daily Profit Focused Stock Screening - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Action & AI Enhanced Trading Signals - newser.com
Will Immuneering Corporation stock outperform value stocksJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Forecasting Immuneering Corporation price range with options dataJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Key metrics from Immuneering Corporation’s quarterly data2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
Is it too late to sell Immuneering CorporationJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Immuneering Corporation stock is in analyst buy zoneJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
Can Immuneering Corporation stock sustain market leadershipLong Setup & Community Trade Idea Sharing - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Immuneering (NASDAQ:IMRX) - MarketBeat
Insider Stock Purchases: October 07, 2025 - Quiver Quantitative
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat
Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Two new option listings and three option delistings on October 2nd - TipRanks
Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World
Insider Stock Purchases: October 01, 2025 - Quiver Quantitative
Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey
Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World
Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria
Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com
Immuneering to host call on pancreatic cancer treatment data - Investing.com
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times
First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan
Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World
To vanquish pancreatic at last? Immuneering scores in phase II - BioWorld MedTech
Immuneering Stock Rises 21.7% on Supply Agreement With LLY - MSN
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst (IMRX) - Seeking Alpha
Mizuho reiterates Outperform rating on Immuneering stock after positive data - Investing.com India
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months - NewsBreak: Local News & Alerts
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):